GeoVax to Report Q3 2025 Financial Results and Provide Business Update
GeoVax Labs will report its third quarter 2025 financial results and provide updates on its clinical-stage vaccine and immunotherapy programs, including COVID-19 vaccines for immunocompromised patients and oncology treatments.
GeoVax Labs, Inc. announced it will report financial results for the quarter ended September 30, 2025, after market close on November 13, 2025. The clinical-stage biotechnology company will host a conference call and webcast at 4:30 p.m. ET to review results and provide a business update covering its pipeline of multi-antigen vaccines and immunotherapies for infectious diseases and cancer.
The upcoming financial disclosure and corporate update carry significant implications for investors and the healthcare sector as GeoVax advances multiple clinical programs. The company's lead COVID-19 vaccine candidate, GEO-CM04S1, is currently in three Phase 2 clinical trials targeting immunocompromised patients, including those with hematologic cancers and chronic lymphocytic leukemia. This development is particularly important given the ongoing need for effective vaccines for vulnerable populations who respond poorly to current authorized COVID-19 vaccines.
Investors can access the live conference call by registering in advance through the company's provided link at https://edge.media-server.com/mmc/p/u86rmdmb/. The webcast will also be available via the Events & Presentations section of GeoVax's Investor Relations website at https://www.geovax.com/investors. Telephone participants should register using the same link to receive dial-in information and unique passcodes.
Beyond its COVID-19 vaccine program, GeoVax's oncology pipeline includes Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox, which has received regulatory guidance from the European Medicines Agency suggesting it may progress directly to Phase 3 clinical evaluation, potentially accelerating its development timeline.
The financial results and business update will provide crucial insights into GeoVax's progress across these diverse therapeutic areas. The company's ability to advance multiple clinical programs simultaneously demonstrates its platform technology's versatility in addressing both infectious diseases and cancer. Investors will be watching for updates on trial progress, regulatory milestones, and financial positioning as the company navigates the capital-intensive biotechnology landscape.
An archived version of the webcast will be available on the company's website approximately two hours after the call concludes and will remain accessible for at least 90 days, allowing interested parties who cannot attend the live event to review the information at their convenience. The comprehensive update comes at a critical time as GeoVax continues to advance its clinical programs toward potential regulatory submissions and commercialization.